The Study On The Clinical Effect And The Influence Factors In Primary Liver Cancer By Invigorating Spleen And Resolving Phlegm

Objective:To evaluate the clinical effect by Invigorating Spleen and Resolving Phlegm and analyze the influence factors.Methods:To select107primary liver cancer outpatients with spleen deficiency as the main symptom from Oncology of Xiyuan Hospital (2009/1/1-2011/12/31) with the treatment by Invigorating Spleen and Resolving Phlegm. To record the clinical symptoms, survival time, tumor objective response, AFP and liver function of each patient and analyze the data statistically.Results:(1) For patients with evaluable target lesions,33cases with total improvement (CR+PR+SD) accounted for30.8%of the population.(2) The total median survival time (MST) of the selected is8.8months with95%CI (9.76,12.23) and the average survival time is10.85months with95%CI (7.49,10.11).(3) Contrasted the survival time of patients with tumor benefit and without portal vein-emboli with that of patients without tumor benefit/with portal vein-emboli respectively with statistical significance (P<0.05), while did that there was no statistical difference (P=0.931>0.05) between patients with lung metastasis and those without.(4) For patients with higher level of AFP, contrasted AFP before and after treatment by Invigorating Spleen and Resolving Phlegm with statistical significance (P=0.021<0.05) and for patients with tumor benefit, did AFP before and after treatment by Invigorating Spleen and Resolving Phlegm without statistical significance (P>0.05)(5) For patients with higher level of TBIL, contrasted TBIL before and after treatment by Invigorating Spleen and Resolving Phlegm with statistical significance (P=0.021<0.05), however, did AST/ALT before and after treatment by Invigorating Spleen and Resolving Phlegm without statistical significance (.P>0.05)(6) The main clinical symptoms before the treatment are less intake, hypochondriac pain, fatigue, abdominal distension, loose stool and jaundice, etc. Statistics showed that treatment by invigorating Spleen and Resolving Phlegm had an effect on less intake, hypochondriac pain, fatigue, jaundice and fever with much improvement, but little effect on splanchneurysma, bleeding, dry stool, dry throat and upset.(7) Contrasted the survival time and find that there was no statistical significance (P=0.567>0.05) between patients with remission and those without remission of symptoms, however, contrasted the symptom scores before and after the treatment with statistical significance (P<0.05)Conclusions:(1) Invigorating Spleen and Resolving Phlegm could benefit primary liver cancer patients in prolonging survival time and tumor objective response. Moreover, patients with tumor benefit could have longer survival time.(2) Distance lung metastasis had little effect on survival time of liver cancer, while it did matter whether the patients were with portal vein-emboli or not. Such showed that Invigorating Spleen and Resolving Phlegm could benefit patients with portal vein-emboli in average survival time at a certain degree.(3) Invigorating Spleen and Resolving Phlegm had no significant effect on ALT/AST of the population, showing that more liver protection is needed coinciding with anti-cancer therapy afterwards.(4) Invigorating Spleen and Resolving Phlegm could decrease AFP at some degree.(5) Invigorating Spleen and Resolving Phlegm had significant effect on hypochondriac pain, less intake, fatigue, jaundice and fever, worthy to be popularized.To conclude that treatment of primary liver cancer by Invigorating Spleen and Resolving Phlegm could improve patients’ symptoms and objective indicators such as liver function and tumor markers at some degree. Some patients could receive tumor remission and longer survival time.